Ampliphi Biosciences Corp’s (APHB) Buy Rating Reaffirmed at HC Wainwright
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday.
Shares of Ampliphi Biosciences Corp (NYSEAMERICAN APHB) opened at $0.86 on Wednesday. Ampliphi Biosciences Corp has a 1 year low of $0.67 and a 1 year high of $9.80.
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.02. Ampliphi Biosciences Corp had a negative net margin of 23,075.00% and a negative return on equity of 313.95%. The firm had revenue of $0.03 million for the quarter.
TRADEMARK VIOLATION WARNING: “Ampliphi Biosciences Corp’s (APHB) Buy Rating Reaffirmed at HC Wainwright” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/15/ampliphi-biosciences-corps-aphb-buy-rating-reaffirmed-at-hc-wainwright.html.
Ampliphi Biosciences Corp Company Profile
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.
Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.